Latest news with #47thAnnualGeneralMeeting
Mint
20-05-2025
- Business
- Mint
Gland Pharma Q4 results: Profit dips 3% YoY to ₹187 crore; 1800% dividend announced
Gland Pharma Q4 Results: Pharma company Gland Pharma on Tuesday, May 20, posted a weak set of numbers for the fourth quarter of the financial year 2024-25 (Q4 FY25), recording a single-digit fall in the consolidated revenue and profit after tax (PAT). Gland Pharma's PAT came in at ₹ 187 crore for the quarter under review, as against ₹ 192 crore in the year-ago quarter, recording a 3% decline on a year-on-year basis. Meanwhile, the revenue from operations declined by 7% YoY to ₹ 1,425 crore in Q4 FY25, from ₹ 1,538 crore in Q4 FY24. On the operating front, the earnings before interest, tax, depreciation and amortisation (EBITDA) also fell 3% YoY to ₹ 348 crore from ₹ 359 crore. The EBITDA margin saw a small uptick to 24% in the March 2024 quarter from 23% in the year-ago period. On a sequential basis, Gland Pharma's revenue rose 3% while PAT was higher by 9%. Shyamakant Giri, Chief Executive Officer of Gland Pharma, commenting on the results, said, 'In Q4 FY25, our consolidated revenue reached INR 14,249 million, with a healthy EBITDA margin of 24%. On the base business, the EBITDA margin expanded to 38%, driven by volume traction in our U.S. portfolio and high-margin new product launches. Cenexi posted modest sequential improvement in revenue and gross margin, and we remain firmly committed to its turnaround.' Going ahead, Giri said the strategic focus would be on accelerating growth in RoW and India, deepening U.S. presence through portfolio enhancement, and continuing to lead on quality and cost efficiency. During the quarter, the company spent ₹ 50.3 crore on research and development (R&D), representing 4.9% of revenue, while for FY25, it was ₹ 1,922 million (4.7% of revenue). In Q4 FY25, Gland Pharma filed five ANDAs and seven got approved, with a total of 24 ANDAs filed and 32 ANDAs approved in FY25, contributing to a cumulative total of 371 ANDA filings in the U.S. (318 approved, 53 pending). Gland Pharma also recommended a final dividend of ₹ 18 or 1800% per equity share of ₹ 1/- each for the financial year 2024-25. The dividend, upon approval by the shareholders, will be paid within 30 days from the date of the 47th Annual General Meeting (AGM), the company said. Furthermore, Gland Pharma also announced the dividend record date. "The record date for the purpose of determining the members eligible to receive the final dividend for the financial year ended March 31, 2025, is Thursday, August 14, 2025," it said.
Mint
20-05-2025
- Business
- Mint
Gland Pharma Q4 results: Profit dips 3% YoY to ₹187 crore; 1800% dividend announced
Gland Pharma Q4 Results: Pharma company Gland Pharma on Tuesday, May 20, posted a weak set of numbers for the fourth quarter of the financial year 2024-25 (Q4 FY25), recording a single-digit fall in the consolidated revenue and profit after tax (PAT). Gland Pharma's PAT came in at ₹ 187 crore for the quarter under review, as against ₹ 192 crore in the year-ago quarter, recording a 3% decline on a year-on-year basis. Meanwhile, the revenue from operations declined by 7% YoY to ₹ 1,425 crore in Q4 FY25, from ₹ 1,538 crore in Q4 FY24. On the operating front, the earnings before interest, tax, depreciation and amortisation (EBITDA) also fell 3% YoY to ₹ 348 crore from ₹ 359 crore. The EBITDA margin saw a small uptick to 24% in the March 2024 quarter from 23% in the year-ago period. On a sequential basis, Gland Pharma's revenue rose 3% while PAT was higher by 9%. Shyamakant Giri, Chief Executive Officer of Gland Pharma, commenting on the results, said, 'In Q4 FY25, our consolidated revenue reached INR 14,249 million, with a healthy EBITDA margin of 24%. On the base business, the EBITDA margin expanded to 38%, driven by volume traction in our U.S. portfolio and high-margin new product launches. Cenexi posted modest sequential improvement in revenue and gross margin, and we remain firmly committed to its turnaround.' Going ahead, Giri said the strategic focus would be on accelerating growth in RoW and India, deepening U.S. presence through portfolio enhancement, and continuing to lead on quality and cost efficiency. During the quarter, the company spent ₹ 50.3 crore on research and development (R&D), representing 4.9% of revenue, while for FY25 was ₹ 1,922 million (4.7% of revenue). In Q4 FY25, Gland Pharma filed five ANDAs and seven got approved, with a total of 24 ANDAs filed and 32 ANDAs approved in FY25, contributing to a cumulative total of 371 ANDA filings in the U.S. (318 approved, 53 pending). Gland Pharma also recommended a final dividend of ₹ 18 or 1800% per equity share of ₹ 1/- each for the financial year 2024-25. The dividend, upon approval by the shareholders, will be paid within 30 days from the date of the 47th Annual General Meeting (AGM), the company said. Furthermore, Gland Pharma also announced the dividend record date. "The record date for the purpose of determining the members eligible to receive the final dividend for the financial year ended March 31, 2025, is Thursday, August 14, 2025," it said. Disclaimer: This story is for educational purposes only. The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
Daily Tribune
17-03-2025
- Business
- Daily Tribune
GPIC reaffirms commitment to petrochemical industry at 47th Annual General Meeting
Gulf Petrochemical Industries Company (GPIC) reinforced its commitment to supporting and developing the petrochemical sector in Bahrain and the wider region during its 47th Annual General Meeting. The meeting was chaired by Kamal bin Ahmed Mohammed, Chairman of the Board. At the outset, the Chairman expressed deep gratitude for the unwavering support of the Nation's wise Leadership, Dr. Mohammed bin Mubarak Bin Daina, Minister of Oil and Environment and Special Envoy for Climate Affairs, as well as the contributions of the company's shareholders and their representatives. Representatives of the shareholders—including Bapco Energies from the Kingdom of Bahrain, SABIC Agri-Nutrients Investment Company from the Kingdom of Saudi Arabia, and Petrochemical Industries Company from the State of Kuwait—commended GPIC's performance. Strong operational performance in 2024 Operational excellence was a key driver of GPIC's success in 2024, with all three production plants exceeding budget expectations: urea by 3.81%, ammonia by 1.21%, and methanol by 0.82%. Equipment upgrades, enhanced production systems, and innovative solutions helped the company achieve a total output of 1.7 million tonnes of ammonia, urea, and methanol, of which 1.2 million tonnes were exported via 63 shipments. These achievements contributed to a net profit of $74 million for the year while maintaining strict cost controls without compromising safety, health, training, or production efficiency. Sustainability and corporate recognition GPIC received several prestigious awards at local, regional, and international levels in 2024, including the HR Summit Award for Best CSR Practices. A major sustainability initiative was the installation of solar panels on parking facility rooftops within the complex, expected to generate 1,072 MWh annually, supporting energy sustainability and reducing the company's carbon footprint. Additionally, GPIC expanded its Mangrove Tree Plantation project, planting over 100,000 mangrove trees to align with Bahrain's national carbon neutrality goals. Acknowledging contributions and future outlook CEO Yasser Al Abbasi praised the dedication of the executive management and employees, crediting their efforts for GPIC's continued success. The 47th Annual General Meeting was attended by Dr. Osama Al-Rais from Bapco Energies representing Bahrain, Ms. Hanadi Ahmed Al-Sindi from Kuwait's Petrochemical Industries Company, and Mr. Iyad Abdulaziz Al-Shaiban from SABIC Agri-Nutrients Investment Company in Saudi Arabia. During the meeting, shareholders approved the distribution of partial dividends, the Board of Directors' report on the company's activities for 2024, and the external auditor's report.
